News | October 08, 2009

Survey Shows Increased Cardiac Issues Due to Economic Downturn

October 8, 2009 – In a recent survey of more than 2,000 U.S. physicians conducted by Epocrates Inc., cardiologists and other specialists shared their perspective on the latest patient visit trends and mobile technology use. With patient visits highly affected by the economy, and the use of technology growing among cardiologists, the company said.

The survey found one in three cardiologists have seen more stress-related cases due to the economy. Nearly 70 percent of the physicians responding to the survey said they have seen an increase in cardiac issues related to stress due to the economic downturn. Due to the economic crisis, more than 85 percent of cardiologists have seen a rise in patients asking for lower cost prescriptions, and more than 65 percent of cardiologists have changed prescriptions based on electronic formulary information.

Nearly all specialists surveyed saw about 30 percent fewer patients in the first half of 2009, and attribute it to the economic downturn. Gastroenterologists and OBGYN physicians report the most decrease.
The survey also found cardiologists and gastroenterologists are the most satisfied with their career choice, but primary care and OBGYN physicians are least satisfied.

For more information: www.epocrates.com


Related Content

News | Pharmaceuticals

Nov. 19, 2025 — Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were ...

Home November 19, 2025
Home
News | Pharmaceuticals

Sept. 25, 2025 — Kardigan has introduced the three late-stage clinical programs leading its robust pipeline, each ...

Home September 25, 2025
Home
News | Pharmaceuticals

Sept. 23, 2025 — CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug ...

Home September 23, 2025
Home
News | Pharmaceuticals

Sept. 2, 2025 —Corsera Health, Inc. has announced its launch with a mission to extend healthspan through cardiovascular ...

Home September 05, 2025
Home
News | Pharmaceuticals

July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that ...

Home July 10, 2024
Home
News | Pharmaceuticals

June 5, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data ...

Home June 05, 2024
Home
News | Pharmaceuticals

May 24, 2024 — Lexicon Pharmaceuticals, Inc. announced a new post-hoc analysis of clinical data showing that INPEFA ...

Home May 24, 2024
Home
News | Pharmaceuticals

May 6, 2024 — Tenax Therapeutics, Inc., a Phase 3, development-stage pharmaceutical company focused on identifying ...

Home May 06, 2024
Home
News | Pharmaceuticals

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
News | Pharmaceuticals

January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...

Home January 25, 2024
Home
Subscribe Now